Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ACTG 303: Follow-up Study to ACTG 175 for HIV-Infected Patients
NCT00001068Phase 2Completed
- Sponsor
- National Institute of Allergy and Infectious Diseases
- Modality
- Small Molecules
- Countries
- 3
01
Overview
A Phase 2 trial of lamivudine in human immunodeficiency virus infection (HIV), sponsored by National Institute of Allergy and Infectious Diseases. Status: completed.
02
Drugs
lamivudine
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT00001068.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00001068.